News headlines about Lexicon Pharmaceuticals (NASDAQ:LXRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.2740515180994 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at $9.90 on Friday. Lexicon Pharmaceuticals has a 52-week low of $8.07 and a 52-week high of $18.00. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The business had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. During the same quarter last year, the business posted ($0.35) earnings per share. The business’s revenue for the quarter was down 2.8% on a year-over-year basis. research analysts anticipate that Lexicon Pharmaceuticals will post -1.43 EPS for the current fiscal year.
A number of research analysts have recently weighed in on LXRX shares. BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th. Needham & Company LLC restated a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Finally, Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $28.50.
In related news, insider Lonnel Coats acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was purchased at an average price of $12.54 per share, for a total transaction of $376,200.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Public Equities L.P. Invus acquired 575,946 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average price of $9.64 per share, with a total value of $5,552,119.44. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 945,353 shares of company stock valued at $9,304,953. 5.77% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-lexicon-pharmaceuticals-lxrx-share-price.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.